Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus U CORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus U CORT.
ARAZLO vs U-CORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
U-CORT (hydrocortisone) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and subsequent anti-inflammatory, immunosuppressive, and metabolic effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses cytokine production and immune cell migration.
Topical: Apply 0.045% gel once daily to affected areas of the face.
U-CORT (hydrocortisone) 100 mg intravenous bolus, followed by 100 mg intravenous every 8 hours for 48 hours, then taper as clinically indicated.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal half-life approximately 1.6-2.2 hours; clinically used as short-acting topical corticosteroid.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily hepatic metabolism; inactive metabolites excreted renally (60-70%) and biliary/fecal (20-30%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid